What's breaking now, across thousands of outlets.
Akeso and its partner Summit Therapeutics proclaimed on Tuesday that their high-profile PD-1xVEGF bispecific hit a major Phase 3 milestone outside of lung cancer. Akeso said ivonescimab met a primary endpoint ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
Five other airport workers are also receiving treatment following the rare outbreak at German's busiest airport.
Spyre Therapeutics said Tuesday it is deprioritizing its antibody candidate for rheumatoid arthritis (RA) after the drug missed the biotech’s bar for success in a mid-stage trial.
Does focusing on negative information lead to depression in kids? A new study suggests the reverse: developing depressive symptoms actually predicts changes in how youth view emotional faces…
A former Air France flight attendant has had her breast cancer recognised as an occupational illness, a first in France. Judges pointed to night shifts, ionising radiation and second-hand smoke.
NMA urges doctors to lead the fight against quackery and unethical practices, stressing that upholding professional ethics is crucial for patient safety an Read More…
